Patents Assigned to Neuromedica, Inc.
-
Patent number: 6107499Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug.In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.Type: GrantFiled: June 6, 1995Date of Patent: August 22, 2000Assignee: Neuromedica, Inc.Inventor: Victor E. Shashoua
-
Patent number: 6080877Abstract: The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and taxotere. The conjugates are useful in treating cancer.Type: GrantFiled: June 3, 1997Date of Patent: June 27, 2000Assignee: Neuromedica, Inc.Inventors: Charles S. Swindell, Victor E. Shashoua, Matthews O. Bradley, Nigel L. Webb
-
Patent number: 5994392Abstract: The invention involves the formation of a prodrug from a fatty acid carrier and a neuroactive drug. The prodrug is stable in the environment of both the stomach and the bloodstream and may be delivered by ingestion. The prodrug passes readily through the blood brain barrier. Once in the central nervous system, the prodrug is hydrolyzed into the fatty acid carrier and the drug to release the drug. In a preferred embodiment, the carrier is 4, 7, 10, 13, 16, 19 docosahexa-enoic acid and the drug is dopamine. Both are normal components of the central nervous system. The covalent bond between the drug and the carrier preferably is an amide bond, which bond may survive the conditions in the stomach. Thus, the prodrug may be ingested and will not be hydrolyzed completely into the carrier molecule and drug molecule in the stomach.Type: GrantFiled: June 5, 1995Date of Patent: November 30, 1999Assignee: Neuromedica, Inc.Inventor: Victor E. Shashoua
-
Patent number: 5977174Abstract: The invention provides compositions that include conjugates of a cholinergic agent and a fatty acid, preferably cis-docosahexaenoic acid. The conjugates are useful in treating disorders resulting from cerebral ischemia including stroke.Type: GrantFiled: November 26, 1997Date of Patent: November 2, 1999Assignee: Neuromedica, Inc.Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
-
Patent number: 5955459Abstract: The invention provides compositions that include conjugates of a fatty acid molecule, preferably cis-docosahexaenoic acid, and antipsychotic agents. The conjugates are usefull in treating psychotic conditions such as schizophrenia.Type: GrantFiled: November 26, 1997Date of Patent: September 21, 1999Assignee: Neuromedica, Inc.Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
-
Patent number: 5919815Abstract: The invention provides taxanes that are conjugates of cis-docosahexaenoic acid and paclitaxel. The conjugates are useful in treating cancer.Type: GrantFiled: May 22, 1996Date of Patent: July 6, 1999Assignee: Neuromedica, Inc.Inventors: Matthews O. Bradley, Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb
-
Patent number: 5795909Abstract: The invention provides conjugates of cis-docosahexaenoic acid and taxanes useful in treating cell proliferative disorders. Conjugates of paclitaxel and docetaxel are preferred.Type: GrantFiled: May 22, 1996Date of Patent: August 18, 1998Assignee: Neuromedica, Inc.Inventors: Victor E. Shashoua, Charles S. Swindell, Nigel L. Webb, Matthews O. Bradley
-
Patent number: 5545719Abstract: This invention describes novel molecules capable of promoting nerve growth, and therapeutic methods for promoting nerve growth using these molecules. Molecules of this invention include a protein fragment substantially homologous to an active region of the brain glycoprotein ependymin. The active region is primarily responsible to the nerve growth promoting capacity of these molecules. The molecules of this invention may be administered to a subject to correct genetic and systemic disorders and to treat nervous systems disorders resulting from trauma.Type: GrantFiled: February 24, 1994Date of Patent: August 13, 1996Assignee: Neuromedica, Inc.Inventor: Victor E. Shashoua
-
Patent number: 5284876Abstract: This invention pertains to a method for treating a subject for Tardive Dyskinesia by administering a dopaminergic agent to the subject such that the dopaminergic agent enters the brain or by administering a prodrug of a therapeutic agent. The dopaminergic agent preferably is 2 prodrug formed by coupling dopamine to a fatty acid. This invention further pertains to methods of providing pharmaceutical preparations and packaged pharmaceuticals for Tardive Dyskinesia.Type: GrantFiled: June 11, 1992Date of Patent: February 8, 1994Assignee: Neuromedica, Inc.Inventors: Victor E. Shashoua, Gary W. Hesse